Origin Agritech Balances Cost Cuts With Growth Bets

Origin Agritech ((SEED)) has held its Q2 earnings call. Read on for the main highlights of the call.

Origin Agritech’s latest earnings call struck a cautiously optimistic tone, pairing clear operational progress with stubborn financial challenges. Management highlighted sharp cost cuts, a rebuilt sales force and a deepening biotech and breeding pipeline, yet also acknowledged a steep revenue drop, continued losses, thin liquidity and heavy reliance on regulatory timing for future growth.

Strategic Restructuring Showing Early Financial Impact

Origin Agritech’s restructuring is starting to show up in the numbers, with total operating expenses down 43.9% to RMB 18.4M and general and administrative costs slashed nearly 70% to RMB 7.6M. Operating loss narrowed by 47.8% to RMB 12.9M and net loss attributable improved 43.8% to RMB 14.4M, signaling better efficiency even as the company remains in the red.

Focused Commercial Investment

While cutting overhead, the company is spending more to reignite growth, nearly doubling selling and marketing expenses to RMB 5.1M as it rebuilds its sales organization to 36 professionals. Management launched the Aoyun 2026 New Variety Promotion Program with KPI-based contracts across six regional sales companies, aiming to convert new products into meaningful market share.

Large and Deepening Breeding Pipeline

R&D spending rose 11.1% to RMB 5.7M as Origin Agritech doubled down on its breeding pipeline, completing over 30,000 test-cross combinations from its 2025 Winter South China program. The company added more than 10,000 new corn combinations via collaborations with over 30 breeders and is using AI-assisted breeding on more than 200,000 germplasm resources to accelerate variety discovery.

Strengthening Biotechnology Credentials and Commercial Readiness

The company underscored its biotech progress, integrating its Hi3 platform with Shunfeng gene-editing tools and leveraging its BBL2-2 biosafety certificate as it prepares for eventual GMO commercialization. Operational readiness improved as GMO crop seed production was added to Beijing Origin’s business scope, the Xinjiang processing facility was restored and a new consortium was set up to monetize biotech services beyond seed sales.

Strategic Talent and Governance Enhancements

Governance upgrades were another focal point, with the appointment of biotech veteran Dr. Jian Zhang to the board and the return of Dr. James Chen as CFO to strengthen capital markets execution. Management also pointed to a direct investment by the CEO in the company as a signal of insider conviction behind the multi-year recovery plan and long-term growth ambitions.

Targeted Variety Acquisitions and Regional Re-entry

On the commercial front, Origin Agritech acquired Zhengtai 889, a top-ranked variety developed with Henan Agriculture University, and Zhongnongda 8538, a strong performer in Northwest China. The company reestablished its regional presence, including a notable reentry into Northeast China via a Changchun showcase event that drew more than 200 dealers and partners to its new product portfolio.

Significant Revenue Decline

Despite operational advances, revenue pressure remains acute, with H1 FY2026 sales falling 31.9% to RMB 49.2M from RMB 72.3M a year earlier. Management attributed the decline primarily to a strategic shift away from external seed tolling services and toward own-brand corn seed product sales, a transition that may depress near-term revenue while targeting higher-quality growth.

Gross Profit and Continued Net Loss

Gross profit slipped to RMB 5.5M from RMB 8.1M, underscoring margin pressure during the business reset, and the company continues to operate at a loss despite year-on-year improvement. Net loss attributable of RMB 14.4M, or RMB 1.21 per share, remains substantial, reminding investors that profitability is still some distance away even as cost controls take hold.

Tighter Liquidity Position and Elevated Liabilities

The balance sheet remains a key watchpoint, with cash and cash equivalents declining to RMB 13.4M from RMB 15.9M as of September 30, 2025. Short-term borrowings edged up to RMB 9.5M and total liabilities rose to RMB 168.1M, leaving the company with a modest cash cushion relative to its obligations and limited room for execution missteps.

Inventory Buildup and Seasonal Risk

Inventories climbed to RMB 24.8M from RMB 14.4M at fiscal year-end, a build management linked to spring planting season and upcoming sales campaigns. While partly seasonal for a seed business, the higher inventory level increases working capital pressure and heightens the risk that any delay in sell-through could strain liquidity further.

Dependence on Regulatory Timing for GMO Commercialization

A major upside driver remains potential GMO commercialization in China, but management stressed that the timing depends on regulatory and policy decisions beyond the company’s control. By declining to forecast when GMO-related revenue might materialize, Origin Agritech signaled both its readiness and the significant uncertainty around this crucial growth catalyst.

Execution Risk: Need to Convert Pipeline into Sales

Management emphasized that the next 12 to 18 months, particularly the second half of FY2026 and first half of FY2027, will test whether its growing pipeline and sales rebuild can translate into commercial traction. With infrastructure and capability strengthened, the key risk now lies in execution—turning R&D and variety acquisitions into sustained revenue and margin improvement.

Forward-Looking Guidance and Long-Term Ambitions

Looking ahead, Origin Agritech believes operating leverage is emerging and expects its rebuilt foundation to begin delivering tangible commercial results by the first half of fiscal 2027. The company is targeting a long-term goal of becoming a top-three corn seed player in China by around 2030–2032, supported by a 36-person KPI-driven sales force, an expanding biotech-enabled R&D engine and strict cost discipline alongside elevated S&M and R&D investment.

Origin Agritech’s earnings call painted the picture of a company midway through a demanding turnaround, with solid structural progress but financial metrics that still demand caution from investors. The coming seasons will reveal whether its heavier bets on sales, biotech and breeding can overcome revenue declines, tight liquidity and regulatory uncertainty to unlock the growth story management is pitching.